Physician profile
Donald John
NPI 1023122686
$3,201.32
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $1,275 · 2021: $980.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $955.56 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $414.73 | 2019-2020 | |
| Amgen INC. | $321.93 | 2019-2021 | |
| Kyowa Kirin, INC. | $244.03 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $184.00 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $158.22 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $153.23 | 2021 | |
| Upsher-Smith Laboratories LLC | $143.17 | 2020 | |
| Ucb, INC. | $120.00 | 2019-2021 | |
| Lundbeck LLC | $113.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $79.03 | 2020-2021 | |
| Allergan, INC. | $49.94 | 2020 | |
| Pfizer INC. | $45.98 | 2021 | |
| Lilly USA, LLC | $45.04 | 2020-2021 | |
| Abbvie INC. | $41.89 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.12 | 2020 | |
| Neurelis, INC. | $30.56 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.92 | 2019 | |
| Eisai INC. | $17.00 | 2021 | |
| Zyla Life Sciences, INC. | $16.89 | 2020 | |
| Mdd US Operations, LLC | $14.32 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.